Publicaciones en las que colabora con Óscar María Beloqui Ruiz (26)

2020

  1. Does chronic kidney disease facilitate malignant myocardial fibrosis in heart failure with preserved ejection fraction of hypertensive origin?

    Journal of Clinical Medicine, Vol. 9, Núm. 2

  2. NADPH oxidase overactivity underlies telomere shortening in human atherosclerosis

    International Journal of Molecular Sciences, Vol. 21, Núm. 4

2016

  1. Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: Potential role of altered collagen metabolism

    Journal of Hypertension, Vol. 34, Núm. 1, pp. 130-138

2013

  1. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients

    Journal of Hypertension, Vol. 31, Núm. 3, pp. 587-594

2011

  1. Association of the peroxisome proliferator-activated receptor α gene L162V polymorphism with stage C heart failure

    Journal of Hypertension, Vol. 29, Núm. 5, pp. 876-883

  2. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: Role of NF-κB

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 31, Núm. 11, pp. 2733-2741

2010

  1. Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]

    FEBS Letters

  2. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease

    Kidney International, Vol. 78, Núm. 12, pp. 1275-1280

2008

  1. Asociación de marcadores inflamatorios y aterosclerosis subclínica en relación con la edad en sujetos sin enfermedad cardiovascular

    Medicina Clinica, Vol. 131, Núm. 10, pp. 361-365

  2. Association between matrix metalloproteinase-10 concentration and smoking in individuals without cardiovascular disease

    Revista Espanola de Cardiologia, Vol. 61, Núm. 12, pp. 1267-1273

2007

  1. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 1, pp. 91-97

  2. Metaloproteasa-10 (estromelisina-2): Un nuevo marcador de aterosclerosis subclínica

    Clinica e Investigacion en Arteriosclerosis, Vol. 19, Núm. 3, pp. 122-128

  3. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: Implications for human atherosclerosis

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, Núm. 3, pp. 587-593

2006

  1. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis

    Journal of the American College of Cardiology, Vol. 47, Núm. 7, pp. 1369-1378

  2. Ciclooxigenasa 2: ¿Una nueva diana terapéutica en la aterosclerosis?

    Medicina Clinica, Vol. 126, Núm. 20, pp. 782-786

  3. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors

    Clinica Chimica Acta, Vol. 368, Núm. 1-2, pp. 138-143

2005

  1. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects

    Journal of Thrombosis and Haemostasis, Vol. 3, Núm. 4, pp. 662-664

  2. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

    Journal of Hypertension, Vol. 23, Núm. 3, pp. 625-632

  3. Monocyte cyclooxygenase-2 activity: A new therapeutic target for atherosclerosis?

    Current Drug Targets - Cardiovascular and Haematological Disorders, Vol. 5, Núm. 4, pp. 303-311

  4. Monocyte cyclooxygenase-2 overactivity: A new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?

    European Heart Journal, Vol. 26, Núm. 2, pp. 153-158